Global adoption of minimally invasive treatments, establishment of the ASAHI brand, and consolidated sales of ¥100 billion
First written in FY2016. 24 of 34 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RaisedAnnual report
「To achieve this long-term management vision, we are reviewing our long-term management targets based on changes in the business environment, progress in each business and future growth opportunities, and aim to achieve consolidated net sales of ¥330 billion and an operating margin of 33% in the fiscal year ending June 2035.」
The long-term targets for the fiscal year ending June 2035 were raised from consolidated net sales of ¥300 billion and an operating margin of 30% to consolidated net sales of ¥330 billion and an operating margin of 33%. - FY2025RaisedAnnual report
「The Group aims to become, as its “desired state in 2035,” a global niche leader in minimally invasive treatment that can comprehensively solve clinical issues, with a mission of contributing to longer healthy lifespans. Its long-term targets are consolidated net sales of ¥300 billion and an operating margin of 30% in the fiscal year ending June 2035.」
The Company has expanded its long-term target from one centered on consolidated net sales exceeding ¥100 billion to a longer-term, higher numerical target of consolidated net sales of ¥300 billion and an operating margin of 30% in the fiscal year ending June 2035. - FY2024AchievedAnnual report
「The Company achieved the medium-term management plan’s milestone of ¥100 billion in consolidated net sales in the fiscal year ended June 2024. Going forward, it aims to expand corporate value by steadily advancing the growth strategies set out in the medium-term management plan.」
The Company specified that it achieved consolidated net sales of ¥100 billion in the fiscal year ended June 2024. At the same time, it continues to pursue its growth strategies and aims to grow further beyond ¥100 billion. - FY2024-Q3RestatedAnnual report
「Under its current medium-term management plan, ASAHI Going Beyond 1000, the Group is developing a business portfolio to grow beyond ¥100 billion in consolidated net sales and has established the following 4 basic policies: ① Strategic development of global markets and expansion of affected areas and treatment fields ② Creation of new businesses in global niche markets ③ Development of an R&D and production structure optimized for global expansion ④ Establishment of a management foundation for sustainable growth By steadily advancing these growth strategies, the Group aims to further enhance corporate value and plans to achieve the major milestone of ¥100 billion in consolidated net sales in the current fiscal year.」
The Company continues to present the 4 basic policies of ASAHI Going Beyond 1000 and the milestone of achieving consolidated net sales of ¥100 billion in the current fiscal year. - FY2024-Q2RestatedAnnual report
「Under its current medium-term management plan, ASAHI Going Beyond 1000, the Group is developing a business portfolio to grow beyond ¥100 billion in consolidated net sales and has established the following 4 basic policies: ① Strategic development of global markets and expansion of affected areas and treatment fields ② Creation of new businesses in global niche markets ③ Development of an R&D and production structure optimized for global expansion ④ Establishment of a management foundation for sustainable growth By steadily advancing these growth strategies, the Group aims to further enhance corporate value and plans to achieve the major milestone of ¥100 billion in consolidated net sales in the current fiscal year.」
The Company continues to present the 4 basic policies of ASAHI Going Beyond 1000 and its target of achieving consolidated net sales of ¥100 billion in the current fiscal year. - FY2024-Q1The Company specified the fiscal year ending March 2026 as the expected timing for achieving consolidated net sales of ¥100 billion.Annual report
「Under its current medium-term management plan, ASAHI Going Beyond 1000, the Group is developing a business portfolio to grow beyond ¥100 billion in consolidated net sales and has established the following 4 basic policies: ① Strategic development of global markets and expansion of affected areas and treatment fields ② Creation of new businesses in global niche markets ③ Development of an R&D and production structure optimized for global expansion ④ Establishment of a management foundation for sustainable growth By steadily advancing these growth strategies, the Group aims to further enhance corporate value and plans to achieve the major milestone of ¥100 billion in consolidated net sales in the current fiscal year.」
The Company continues to pursue the 4 basic policies of ASAHI Going Beyond 1000 and specified that its previous long-term target of ¥100 billion in consolidated net sales is scheduled to be achieved in the current fiscal year. - FY2023-Q3RestatedAnnual report
「By pursuing minimally invasive treatment to the fullest, the Company aims to improve the QOL of physicians and patients. It is advancing the development of a business portfolio under the new medium-term management plan “ASAHI Going Beyond 1000,” with a target of exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026 and achieving further long-term growth over the next 10 years. The plan sets out the following 4 basic policies.」
The Company continues to pursue improved QOL through minimally invasive treatment, consolidated net sales exceeding ¥100 billion in the fiscal year ending June 2026, and the long-term growth framework under ASAHI Going Beyond 1000. - FY2023-Q2RestatedAnnual report
「By pursuing minimally invasive treatment to the fullest, the Company aims to improve the QOL of physicians and patients. It is advancing the development of a business portfolio under the new medium-term management plan “ASAHI Going Beyond 1000,” with a target of exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026 and achieving further long-term growth over the next 10 years. The plan sets out the following 4 basic policies.」
The Company continues to pursue improved QOL through minimally invasive treatment, consolidated net sales exceeding ¥100 billion in the fiscal year ending June 2026, and the long-term growth policy under ASAHI Going Beyond 1000. - FY2023-Q1RestatedAnnual report
「By pursuing minimally invasive treatment to the fullest, the Company aims to improve the QOL of physicians and patients. It is advancing the development of a business portfolio under the new medium-term management plan “ASAHI Going Beyond 1000,” with a target of exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026 and achieving further long-term growth over the next 10 years. The plan sets out the following 4 basic policies.」
The Company continues to pursue ASAHI Going Beyond 1000, which targets consolidated net sales exceeding ¥100 billion in the fiscal year ending June 2026, together with policies to improve QOL through minimally invasive treatment and achieve long-term growth. - FY2022RestatedAnnual report
「The Company has established a management vision of “creating innovation through ASAHI TECHNOLOGY together with professionals around the world, identifying the needs of next-generation healthcare and industry, and solving global issues globally,” and aims to continue growing beyond ¥100 billion in consolidated net sales as its long-term target.」
The Company continues to pursue innovation through ASAHI TECHNOLOGY and the resolution of global issues, with a long-term target of consolidated net sales exceeding ¥100 billion. - FY2022-Q2RestatedAnnual report
「By pursuing minimally invasive treatment to the fullest, the Company aims to improve the QOL of physicians and patients. It is advancing the development of a business portfolio under the new medium-term management plan “ASAHI Going Beyond 1000,” with a target of exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026 and achieving further long-term growth over the next 10 years. The plan sets out the following 4 basic policies.」
The Company continues to pursue consolidated net sales exceeding ¥100 billion in the fiscal year ending June 2026 and the 4 basic policies of ASAHI Going Beyond 1000. - FY2022-Q1ReframedAnnual report
「By pursuing minimally invasive treatment to the fullest, the Company aims to improve the QOL of physicians and patients. It is advancing the development of a business portfolio under the new medium-term management plan “ASAHI Going Beyond 1000,” with a target of exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026 and achieving further long-term growth over the next 10 years. The plan sets out the following 4 basic policies.」
Under the new medium-term management plan “ASAHI Going Beyond 1000,” the Company has specified its previous long-term target as exceeding ¥100 billion in consolidated net sales in the fiscal year ending June 2026. - FY2021ReframedAnnual report
「The Company has established a management vision of “creating innovation through ASAHI TECHNOLOGY together with professionals around the world, identifying the needs of next-generation healthcare and industry, and solving global issues globally,” and aims to continue growing beyond ¥100 billion in consolidated net sales as its long-term target.」
The Company has updated its long-term vision from one centered on minimally invasive treatment and the ASAHI brand to one focused on innovation through ASAHI TECHNOLOGY with professionals worldwide and solving global issues, and has expanded its sales target to continued growth beyond ¥100 billion. - FY2021-Q3RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses. By continuing to invest in growth toward the future, it aims to create new businesses in global niche markets, strengthen its presence in those markets and further enhance corporate value. To support this growth strategy, the Group is developing a business foundation consisting of an R&D and production structure optimized for global expansion and a management foundation for sustainable growth. Under the plan, the Group aims to achieve consolidated net sales of ¥80 billion in the fiscal year ending June 2023 as a milestone toward ¥100 billion, with an operating margin target of approximately 25% at that point.」
The Company continues to pursue the long-term ASAHI Road to 1000 target, the interim targets of ¥80 billion in net sales and a 25% operating margin for the fiscal year ending June 2023, and business portfolio development. - FY2021-Q2RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses. By continuing to invest in growth toward the future, it aims to create new businesses in global niche markets, strengthen its presence in those markets and further enhance corporate value. To support this growth strategy, the Group is developing a business foundation consisting of an R&D and production structure optimized for global expansion and a management foundation for sustainable growth.」
Under ASAHI Road to 1000, the Company continues to develop its business portfolio toward consolidated net sales of ¥100 billion, strengthen the earnings base of its existing businesses, create new businesses, and establish its R&D, production and management foundations. - FY2021-Q1RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to present the long-term target of ¥100 billion in consolidated net sales under the five-year ASAHI Road to 1000 plan, together with the business portfolio development required to achieve it. - FY2020RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2020-Q3RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under ASAHI Road to 1000, the Company continues to pursue business portfolio development and earnings-base enhancement toward consolidated net sales of ¥100 billion. - FY2020-Q2RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under ASAHI Road to 1000, the Company continues to build its business portfolio and strengthen the earnings base of its existing businesses toward the long-term target of ¥100 billion in consolidated net sales. - FY2019RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2019-Q3RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2019-Q2RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2019-Q1RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2018RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2018-Q2RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2018-Q1RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2017RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2017-Q3RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2017-Q2RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term targets of global adoption of minimally invasive treatment products, improved patient QOL, establishment of the ASAHI brand and consolidated net sales of ¥100 billion. - FY2017-Q1RestatedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company continues to pursue its long-term management vision and target of ¥100 billion in consolidated net sales. - FY2016First statedAnnual report
「The Company has established a management vision of “actively promoting the adoption of minimally invasive treatment products from Japan to the world, improving the quality of life (QOL) of patients worldwide, and establishing the ASAHI brand globally,” and has set a long-term target of ¥100 billion in consolidated net sales.」
The Company’s long-term vision is to promote minimally invasive treatment, improve patient QOL and establish a global brand, with consolidated net sales of ¥100 billion as its numerical target.